TenNor Therapeutics held its first Clinical Advisory Meeting on TNP-2092 for the treatment of prosthetic joint infections (PJIs) during the American Association of Hip and Knee Surgeons (AAHKS) Meeting in San Francisco on May 5, 2017.

The meeting was chaired by Dr. Javad Parvizi, MD, from the Rothman Institute who is a world leading expert in the management of PJIs. The meeting was attended in person or by phone by seven other opinion leaders in the field. Dr. Zhenkun Ma, PhD, Founder and CEO, presented the background information on TNP-2092 and Dr. Martino Laurenzi, MD, Chief Medical Officer, presented the clinical development plan and study protocols. On behalf of TenNor, Xiaomei Wang, Head of Clinical Operation, Dr. Mark Goldberger, MD, regulatory consultant and Aaron Dane, statistician and clinical development consultant also attended the meeting.

Treatment of PJIs is one of the major unmet medical needs in the infectious disease area. With population aging, the number of total hip and knee replacement surgeries is increasing rapidly and projected to reach 4 million by 2030 in the United States. Despite the best prevention efforts, the incidence rate for PJIs remains 1-3%. PJIs are difficult to treat, often requiring implant replacement surgery accompanied by prolonged antibiotic therapy. PJIs are a major health problem for the patients and associated with high cost to the healthcare system.

TNP-2092 is a multi-targeting antibacterial agent with potent activity against major pathogens associated with PJIs living in bacterial biofilms. It has the potential to improve the management of PJIs and is currently under clinical development by TenNor. The Advisory Group is encouraged by the development of TNP-2092 and provided valuable inputs to the clinical development plan and to the PJI study protocol.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com